Advent Life Sciences

Advent Life Sciences is a leading transatlantic venture capital firm focused on building innovative life sciences businesses in the UK, Europe and the USA. The firm founds and invests in early- and mid-stage companies with a first-in-class or best-in-class approach to unmet medical needs, principally in new drug discovery across all modalities (small molecules, biologics, and new modalities), med tech, enabling technologies, and vaccines. Since 2006, Advent-backed companies have brought fifteen innovative medicines and products to approval, with initial investments often as early as Seed or Series A stage. As entrepreneurs and experienced, pragmatic investors, the team brings deep intellectual capital and takes a hands-on approach, working in close alignment and partnership with management teams to realise their vision. Their investment and company-building process focuses on understanding the true essence of the innovation, its competitive relevance, and agreeing the scientific and clinical approach, operating plan, team development, syndication, and financing strategy — the five key elements to building a great biotech company — with the goal of achieving superior financial returns by bringing innovation to patients.